Approximately 10%–30% of breast cancer patients develop brain metastases, with an especially high risk observed in HER-2-positive metastatic breast cancer patients, where the cumulative incidence reaches as high as 50%. The gene discussed is ERBB2; the disease is breast carcinoma.